查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2015189

帕金森氏症治療市場：2026-2030年全球市場預測（按藥物類別、治療方法、給藥途徑、標靶區、分銷管道和最終用戶分類）

Parkinson's Disease Therapeutics Market by Drug Class, Therapy Type, Route Of Administration, Targeted Area, Distribution Channel, End User - Global Forecast 2026-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年帕金森氏症治療市場價值為 54.3 億美元，預計到 2025 年將成長至 57.6 億美元，複合年成長率為 6.29%，到 2030 年將達到 78.3 億美元。

主要市場統計數據
基準年 2024 54.3億美元
預計年份：2025年 57.6億美元
預測年份 2030 78.3億美元
複合年成長率 (%) 6.29%

權威框架闡述了帕金森氏症治療的複雜性、各個階段未滿足的需求以及臨床開發和商業性成功的策略重點。

帕金森氏症仍然是臨床醫生、研究人員、保險公司和產業界面臨的最複雜的神經退化性疾病之一。過去十年，治療研發已從症狀治療、單一標靶療法轉向綜合策略，結合了複雜的多巴胺能調節、神經保護假說和輔助性非藥物療法。本文總結了目前的治療現狀，指出了疾病各個階段尚未滿足的需求，並提出了策略性挑戰，以指導決策者在評估投資、設計臨床項目或確定投資組合優先事項時做出決策。

科學進步、精確的表現型分析和真實世界數據如何重塑帕金森氏症治療的提供方式，並創造新的策略轉折點。

帕金森氏症治療格局正經歷一場變革，這主要得益於科學進步、不斷完善的治療標準以及跨部門合作。近年來，藥物類別、輔助性治療和基於器械的給藥平台的創新發展迅速，促使人們重新評估臨床路徑和治療順序。雖然精準的表現型分析和生物標記的應用提高了臨床試驗的患者招募率和療效解讀，但神經調控療法和復健治療的進步正將非藥物療法的作用從單純的輔助手段提升為必不可少的補充療法。

對美國關稅變化到 2025 年將如何重塑藥品供應鏈的韌性、價格壓力和商業化策略進行定性分析。

近期政策週期中新關稅政策和貿易措施的訂定，令全球製藥和醫療設備製造商的供應鏈規劃變得更加複雜。在美國，已宣布的2025年累積關稅調整迫使製造商重新思考其採購、庫存策略以及帕金森氏症治療中常用原料、成品製劑和醫療設備組件的定價方法。本節將透過定性機制分析關稅趨勢如何影響產業經濟和營運韌性，同時避免進行推測性的量化分析。

針對藥物類別、治療方法、給藥途徑、患者亞型、分銷管道和最終用戶環境等關鍵細分訊息，明確策略。

有效的市場區隔對於帕金森氏症治療藥物的開發和商業化策略至關重要。在按藥物類別分析市場時，相關人員需要了解不同藥物的獨特臨床特徵和市場定位，例如抗膽鹼能藥物（包括苯扎托品和苯海索）、COMT抑制劑、多巴胺促效劑、左旋多巴和MAO-B抑制劑。每種藥物都針對不同的症狀群和長期管理挑戰。治療方法細分區分了傳統的藥物介入和非藥物療法，例如深部腦部刺激、物理治療和語言治療。這些非藥物療法在疾病進展的各個階段都發揮著日益重要的策略作用，影響著患者的用藥依從性、治療效果和支付者的接受度。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和支付方環境正在影響著醫療服務的取得、普及和商業策略。

區域趨勢對治療方法的採納、監管時間表和支付方的預期都產生顯著影響。在美洲，人口老化和成熟的專業醫療保健網路正在推動對藥物和醫療設備解決方案的需求。同時，在支付方體系中，療效比較和預算影響的證據對於報銷決策至關重要。跨境生產和分銷模式進一步影響產品的供應和物流，該地區的相關人員通常優先考慮快速獲取途徑和基於價值的合作合約模式。

競爭動態、生物製藥和醫療設備創新者之間的合作以及基於結果的方法如何重新定義企業策略和差異化。

隨著新型作用機制、改進的給藥系統和整合式照護模式的出現，帕金森氏症治療領域的競爭動態正在改變。曾經主導多巴胺促效劑療法的老牌製造商如今面臨來自生技公司（致力於緩解疾病療法）和醫療設備製造商（提供新一代神經調控和輸注技術）的競爭。策略聯盟和許可協議正日益彌合分子水平創新與醫療設備驅動的給藥技術之間的差距，創造出兼具價值和吸引力的混合型提案，以滿足臨床醫生和患者對改善症狀管理和減輕治療負擔的需求。

為行業領導者提供可操作的策略性舉措，以協調生物標記驅動的開發、具有韌性的供應鏈和以結果主導的商業化。

業界領導者應採取切實可行的措施，將科學研究機會與實際的給藥和報銷方案結合。首先，將轉化生物標記項目納入研發計劃，有助於更好地進行患者分層，並提高標靶治療獲得監管機構和支付方核准的可能性。其次，建造靈活的製造地和供應商冗餘機制，有助於緩解關稅波動和零件短缺等外部衝擊，同時確保按時上市並保障患者獲得治療。第三，制定跨部門的證據計劃，結合隨機對照試驗、可操作性研究和真實世界註冊研究，能夠解決包括監管機構、支付方和臨床醫生在內的眾多相關人員的關切。

採用透明的調查方法，結合專家訪談、二手科學資訊來源和情境分析，檢驗策略見解和限制。

本研究整合了一手和二手資料，建立了嚴謹且可重複的方法論基礎。一手資料收集包括對臨床專業人員、藥劑師、支付方代表和行業相關人員進行結構化訪談，以了解治療應用、獲取障礙和證據需求等方面的真實觀點。二手分析利用同儕審查文獻、監管申報文件、臨床試驗註冊庫和公共文件，對研究結果進行三角驗證，確保科學準確性。分析方法結合了定性主題編碼和情境檢驗，以評估監管變化、供應鏈趨勢和相關人員期望的影響。

將科學創新與策略需求結合，結合切實可行的商業化和進入策略，為患者帶來影響。

帕金森氏症治療格局正處於一個轉折點，科學進步、給藥方式創新以及相關人員不斷變化的期望在此交匯融合。藥物研發的進步，輔以改進的給藥形式和非藥物干預措施，為更全面地解決運動和非運動症狀創造了機會。然而，新的政策壓力、日益複雜的供應鏈以及患者亞型的多樣性，都要求企業採取整合策略，將臨床開發與實際商業化和可及性考量相結合。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：帕金森氏症治療市場：依藥物類別分類

  • 抗膽鹼能藥物
    • 苯扎托品
    • 三己安非他命
  • COMT抑制劑
    • entacapone
    • 托魯卡蓬
  • 多巴胺促效劑
  • 左多巴
  • MAO-B抑制劑

第9章：帕金森氏症治療市場（依治療方法分類）

  • 藥物治療
  • 非藥物療法
    • 深部腦部刺激療法
    • 物理治療
    • 語言治療

第10章：帕金森氏症治療市場：依給藥途徑分類

  • 靜脈注射
  • 注射藥物
  • 口服
  • 經皮

第11章：按目標區域分類的帕金森氏症治療市場

  • 非典型帕金森症候群
  • 藥物誘發的帕金森氏症候群
  • 遺傳性帕金森氏症
  • 特發性帕金森氏症
  • 血管型帕金森症候群

第12章：帕金森氏症治療藥物市場：依分銷管道分類

  • 離線
    • 醫院藥房
    • 零售藥房
  • 線上

第13章：帕金森氏症治療市場：依最終用戶分類

  • 診所
  • 居家照護
  • 醫院

第14章：帕金森氏症治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：帕金森氏症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：帕金森氏症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國帕金森氏症治療市場

第18章：中國帕金森氏症治療市場

第19章 競爭情勢

  • 2024年市場集中度分析
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2024 年
  • 2024年產品系列分析
  • 基準分析，2024 年
  • AbbVie Inc.
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Limited
Product Code: MRR-036C5CF3B54D

The Parkinson's Disease Therapeutics Market was valued at USD 5.43 billion in 2024 and is projected to grow to USD 5.76 billion in 2025, with a CAGR of 6.29%, reaching USD 7.83 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 5.43 billion
Estimated Year [2025] USD 5.76 billion
Forecast Year [2030] USD 7.83 billion
CAGR (%) 6.29%

An authoritative framing of Parkinson's therapeutic complexity, unmet needs across stages, and strategic priorities for clinical development and commercial success

Parkinson's disease remains one of the most complex neurodegenerative disorders confronting clinicians, researchers, payers, and industry alike. Over the last decade, therapeutic development has shifted from symptomatic mono-target approaches toward integrated strategies that combine refined dopaminergic modulation, neuroprotective hypotheses, and supportive non-pharmacological interventions. This introduction synthesizes the current therapeutic posture, clarifies unmet clinical needs across disease stages, and frames the strategic imperatives that should guide decision-makers when evaluating investment, clinical program design, or portfolio prioritization.

Emerging clinical evidence and real-world practice patterns have both exposed gaps and revealed opportunities. While levodopa continues to underpin motor symptom control, long-term motor complications, heterogeneity in non-motor symptom burden, and differential patient responses highlight the need for diversified treatment paradigms. Concurrently, innovations in delivery technologies and multidisciplinary care models have shown promise in improving function and quality of life. Taken together, these dynamics demand a nuanced understanding of therapeutic value that spans efficacy, durability, tolerability, ease of administration, and system-level adoption pathways. This introduction sets the stage for a deeper examination of landscape shifts, policy impacts, segmentation intelligence, regional nuances, and practical recommendations for industry leaders seeking to navigate a rapidly evolving therapeutic ecosystem.

How scientific advances, precision phenotyping, and real-world evidence are reshaping Parkinson's care delivery and creating new strategic inflection points

The therapeutic landscape for Parkinson's disease is undergoing transformative shifts driven by scientific advances, evolving standards of care, and cross-sector collaboration. Over recent years, the field has witnessed accelerated innovation in drug classes, adjunctive therapies, and device-enabled delivery platforms, prompting a reassessment of clinical pathways and treatment sequencing. Precision in patient phenotyping and biomarker use has improved trial enrolment and response interpretation, while advances in neuromodulation and rehabilitation are elevating the role of non-pharmacological interventions as essential complements rather than mere adjuncts.

Simultaneously, real-world evidence generation and adaptive trial designs are shortening development cycles and enabling more responsive go/no-go decisions for late-stage programs. Health-system stakeholders are increasingly focused on outcomes that matter to patients, such as activities of daily living and caregiver burden, which has led to wider acceptance of multidimensional endpoints in clinical development and reimbursement discussions. As a result, companies that integrate translational science with pragmatic deployment strategies and stakeholder-aligned evidence plans will be better positioned to capture clinical and economic value. This section elaborates on these paradigm changes and identifies the critical inflection points that industry players should monitor closely.

Qualitative analysis of how United States tariff shifts through 2025 reshape supply chain resilience, pricing pressure, and commercialization strategies in therapeutics

The introduction of new tariff policies and trade measures in recent policy cycles has complicated supply chain planning for global pharmaceutical and device manufacturers. In the United States context, cumulative tariff adjustments announced through 2025 have prompted manufacturers to reassess sourcing, inventory strategy, and pricing approaches for components, finished dosage forms, and device elements commonly used in Parkinson's therapeutics. This section analyzes the qualitative mechanisms through which tariff dynamics influence industry economics and operational resilience, while avoiding speculative quantification.

Tariff-induced cost pressures often cascade across manufacturing and distribution chains. When import duties affect raw materials, excipients, or specialized components for infusion pumps or delivery systems, manufacturers face trade-offs between passing costs to payers and patients, absorbing margin compression, or relocating production. Logistics complexity and customs processing can extend lead times, increasing the need for safety stocks and flexible supply agreements. Moreover, tariff volatility introduces procurement risk that can dampen investment in capital-intensive programs or delay commercialization timelines. From a payer and provider perspective, increased acquisition costs can shift formulary decisions and favor products with differentiated value propositions justified by clinical benefits or lower total cost of care.

To mitigate these headwinds, companies are increasingly pursuing supplier diversification, nearshoring of critical manufacturing steps, and longer-term procurement contracts. They are also accelerating regulatory and quality alignment for alternate production sites to preserve continuity of supply. In summary, tariff shifts through 2025 have reinforced the imperative for integrated supply chain strategies that align manufacturing footprint decisions with clinical development and commercialization plans, ensuring both resilience and the ability to sustain innovation.

Key segmentation intelligence across drug classes, therapy modalities, administration routes, patient subtypes, distribution channels, and end-user settings to sharpen strategy

Robust segmentation is central to effective development and commercialization strategies for Parkinson's therapeutics. When examining the market by drug class, stakeholders should recognize the distinct clinical profiles and positioning of Anticholinergics, which include Benztropine and Trihexyphenidyl, alongside COMT inhibitors, Dopamine agonists, Levodopa, and MAO-B inhibitors, each of which addresses different symptom clusters and long-term management questions. Therapy type segmentation separates traditional pharmacologic interventions from Non-Pharmacological Therapies where modalities such as Deep Brain Stimulation, Physiotherapy, and Speech & Language Therapy play increasingly strategic roles across disease stages, influencing adherence, outcomes, and payer acceptance.

Route of administration segmentation highlights how infusion, injectable, oral, and transdermal formats create distinct value propositions related to onset of action, patient convenience, and caregiver burden. Targeted area classification-spanning Atypical Parkinsonian, Drug-Induced Parkinsonism, Genetic Parkinson's, Idiopathic Parkinson's, and Vascular Parkinsonism-underscores the heterogeneity of etiologies and the implication that clinical development must be tailored to pathophysiology and progression patterns. Distribution channel perspectives differentiate Offline models such as Hospital Pharmacy and Retail Pharmacy from Online Pharmacy, with each channel dictating distinct patient access, adherence support, and commercial engagement tactics. Finally, end-user segmentation that includes Clinics, Home Care, and Hospitals emphasizes that product adoption hinges on workflows, reimbursement pathways, and the capacity of care settings to deliver specialized services. Integrating these segmentation lenses enables sponsors to prioritize development assets, design targeted evidence generation, and craft differentiated launch strategies that resonate with clinical and payer stakeholders.

Regional dynamics and payer landscapes across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine access, adoption, and commercial strategy

Regional dynamics exert significant influence on therapeutic adoption, regulatory timelines, and payer expectations. In the Americas, demographic aging and well-established specialty care networks drive demand for both pharmacologic and device-based solutions, while payer ecosystems emphasize comparative effectiveness and budget impact evidence in reimbursement decisions. Cross-border manufacturing and distribution practices further shape availability and logistics, and stakeholders in this region often prioritize rapid access pathways and collaborative value-based contracting models.

Across Europe, Middle East & Africa, diverse regulatory frameworks and heterogeneous reimbursement landscapes create both obstacles and opportunities for differentiated strategies. High-income markets in Western Europe typically demand robust health technology assessment packages and real-world outcomes, whereas emerging markets in the broader region may value scalable, cost-effective interventions and simplified delivery models. Regional disparities in specialist access and infrastructure mean that partnerships with local health systems and investment in capacity-building are critical for meaningful adoption.

In the Asia-Pacific region, rapid adoption of innovative delivery technologies and strong governmental support for domestic manufacturing are shaping competitive dynamics. Demographic and epidemiological trends, combined with growing private and public payer sophistication, incentivize tailored pricing and market access approaches. Taken together, these regional nuances require adaptive go-to-market plans, targeted evidence generation, and stakeholder engagement models that reflect local care pathways and decision-making processes.

How competitive dynamics, alliances between biologics and device innovators, and outcomes-based approaches are redefining company strategies and differentiation

Competitive dynamics in Parkinson's therapeutics are evolving as incumbent product lines face pressure from novel mechanisms, enhanced delivery systems, and integrated care models. Established manufacturers that have historically dominated dopaminergic therapies are now contending with biotech entrants advancing disease-modifying concepts, as well as medtech firms delivering next-generation neuromodulation and infusion technologies. Strategic alliances and licensing transactions increasingly bridge gaps between molecular innovation and device-enabled delivery, creating hybrid value propositions that appeal to clinicians and patients seeking improved symptom control and reduced treatment burden.

The operating landscape also reflects a rising emphasis on post-approval evidence generation, as payers request real-world outcomes and registries to demonstrate longitudinal benefit. Companies that invest early in outcomes-based agreements and patient support infrastructure improve the probability of favorable formulary positioning. Additionally, manufacturers focusing on ease of administration, caregiver support, and integration with home-care models gain competitive advantage in settings where outpatient management is expanding. Overall, leaders in this space combine strong clinical data, thoughtful channel strategies, and partnerships that accelerate adoption across care settings while addressing systemic challenges such as workforce limitations and cost containment pressures.

Practical strategic initiatives for industry leaders to align biomarker-enabled development, resilient supply chains, and outcomes-driven commercialization

Industry leaders should adopt actionable initiatives that align scientific opportunity with pragmatic delivery and reimbursement realities. First, integrating translational biomarker programs with development plans will improve patient stratification and increase the likelihood of regulatory and payer acceptance for targeted therapies. Second, building flexible manufacturing footprints and supplier redundancy helps mitigate external shocks such as tariff shifts or component shortages, preserving launch timelines and access commitments. Third, cultivating cross-functional evidence plans that combine randomized trials, pragmatic studies, and real-world registries will address the broad spectrum of stakeholder concerns from regulators to payers and clinicians.

Leaders should also prioritize partnerships across clinical, technological, and service domains to accelerate time-to-value. Collaborations with device developers, digital health firms, and rehabilitation specialists can create differentiated, bundled care offerings that better meet patient needs. In parallel, proactive engagement with payers to explore outcomes-based reimbursement and pilot programs can reduce adoption friction. Finally, investing in patient and caregiver support services enhances adherence and demonstrates commitment to real-world impact. Collectively, these actions create durable differentiation and position organizations to convert scientific progress into sustainable clinical and commercial success.

A transparent research methodology combining primary expert interviews, secondary scientific sources, and scenario analysis to validate strategic insights and limitations

This research synthesizes primary and secondary sources to create a rigorous, reproducible methodological foundation. Primary data collection included structured interviews with clinical experts, pharmacists, payer representatives, and industry stakeholders to capture real-world perspectives on therapeutic use, access barriers, and evidence needs. Secondary analysis drew on peer-reviewed literature, regulatory submissions, clinical trial registries, and public policy documents to triangulate findings and ensure scientific fidelity. Analytical approaches combined qualitative thematic coding with scenario analysis to evaluate the implications of regulatory changes, supply chain dynamics, and stakeholder expectations.

Throughout the research, emphasis was placed on transparency and validation. Key insights were cross-checked against multiple independent sources and, where possible, validated with clinicians and health-system decision-makers. Limitations are acknowledged: rapidly evolving clinical data and policy developments require periodic updates, and some operational variables may differ across specific national contexts. Nonetheless, the methodology delivers an actionable synthesis that supports strategic decision-making, helps prioritize evidence generation, and informs commercialization and access strategies across therapeutic modalities and geographies.

A synthesis of the strategic imperative to combine scientific innovation with pragmatic commercialization and access strategies to deliver patient impact

The therapeutic environment for Parkinson's disease is at an inflection point where scientific progress, delivery innovation, and shifting stakeholder expectations converge. Advances in pharmacology are being complemented by enhanced delivery formats and non-pharmacological interventions, creating opportunities to address both motor and non-motor symptoms more comprehensively. However, new policy pressures, supply chain complexities, and the heterogeneity of patient subtypes demand that companies adopt integrated strategies that align clinical development with pragmatic commercialization and access considerations.

Successful strategies will balance rigorous evidence generation with operational resilience and stakeholder engagement. Firms that prioritize patient-centered outcomes, invest in flexible manufacturing and supply solutions, and craft regionally adapted market access plans are best positioned to translate innovation into meaningful clinical impact. In closing, the pathway to success lies in combining scientific rigor with pragmatic execution, ensuring that therapeutic advances reach patients efficiently and sustainably while meeting the expectations of clinicians, payers, and health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Parkinson's Disease Therapeutics Market, by Drug Class

  • 8.1. Anticholinergics
    • 8.1.1. Benztropine
    • 8.1.2. Trihexyphenidyl
  • 8.2. COMT Inhibitors
    • 8.2.1. Entacapone
    • 8.2.2. Tolcapone
  • 8.3. Dopamine Agonists
  • 8.4. Levodopa
  • 8.5. MAO-B Inhibitors

9. Parkinson's Disease Therapeutics Market, by Therapy Type

  • 9.1. Medications
  • 9.2. Non-Pharmacological Therapies
    • 9.2.1. Deep Brain Stimulation
    • 9.2.2. Physiotherapy
    • 9.2.3. Speech & Language Therapy

10. Parkinson's Disease Therapeutics Market, by Route Of Administration

  • 10.1. Infusion
  • 10.2. Injectable
  • 10.3. Oral
  • 10.4. Transdermal

11. Parkinson's Disease Therapeutics Market, by Targeted Area

  • 11.1. Atypical Parkinsonian
  • 11.2. Drug-Induced Parkinsonism
  • 11.3. Genetic Parkinson's
  • 11.4. Idiopathic Parkinson's
  • 11.5. Vascular Parkinsonism

12. Parkinson's Disease Therapeutics Market, by Distribution Channel

  • 12.1. Offline
    • 12.1.1. Hospital Pharmacy
    • 12.1.2. Retail Pharmacy
  • 12.2. Online

13. Parkinson's Disease Therapeutics Market, by End User

  • 13.1. Clinics
  • 13.2. Home Care
  • 13.3. Hospitals

14. Parkinson's Disease Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Parkinson's Disease Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Parkinson's Disease Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Parkinson's Disease Therapeutics Market

18. China Parkinson's Disease Therapeutics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2024
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2024
  • 19.3. Product Portfolio Analysis, 2024
  • 19.4. Benchmarking Analysis, 2024
  • 19.5. AbbVie Inc.
  • 19.6. Bayer AG
  • 19.7. Biogen Inc.
  • 19.8. Bristol-Myers Squibb Company
  • 19.9. Eisai Co., Ltd.
  • 19.10. Eli Lilly and Company
  • 19.11. F. Hoffmann-La Roche Ltd.
  • 19.12. GlaxoSmithKline plc
  • 19.13. Merck & Co., Inc.
  • 19.14. Otsuka Pharmaceutical Co., Ltd.
  • 19.15. Pfizer Inc.
  • 19.16. Teva Pharmaceutical Industries Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 2. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 14. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 2. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 3. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
  • TABLE 7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY BENZTROPINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY BENZTROPINE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY BENZTROPINE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRIHEXYPHENIDYL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRIHEXYPHENIDYL, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRIHEXYPHENIDYL, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ENTACAPONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ENTACAPONE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ENTACAPONE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TOLCAPONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TOLCAPONE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TOLCAPONE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE AGONISTS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE AGONISTS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY LEVODOPA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY LEVODOPA, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY LEVODOPA, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO-B INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO-B INHIBITORS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO-B INHIBITORS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DEEP BRAIN STIMULATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DEEP BRAIN STIMULATION, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DEEP BRAIN STIMULATION, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SPEECH & LANGUAGE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SPEECH & LANGUAGE THERAPY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SPEECH & LANGUAGE THERAPY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INFUSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INFUSION, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INFUSION, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ATYPICAL PARKINSONIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ATYPICAL PARKINSONIAN, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ATYPICAL PARKINSONIAN, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG-INDUCED PARKINSONISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 67. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG-INDUCED PARKINSONISM, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 68. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG-INDUCED PARKINSONISM, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GENETIC PARKINSON'S, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 70. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GENETIC PARKINSON'S, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 71. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GENETIC PARKINSON'S, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 72. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY IDIOPATHIC PARKINSON'S, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 73. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY IDIOPATHIC PARKINSON'S, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 74. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY IDIOPATHIC PARKINSON'S, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 75. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY VASCULAR PARKINSONISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 76. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY VASCULAR PARKINSONISM, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 77. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY VASCULAR PARKINSONISM, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 78. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 80. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 81. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 83. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 84. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 85. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 86. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 87. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 88. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 90. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 91. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 92. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 94. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 95. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 96. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 97. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 98. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 99. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 100. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 101. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 102. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 103. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
  • TABLE 104. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
  • TABLE 106. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 107. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 109. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 111. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 113. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 115. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
  • TABLE 117. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 118. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 120. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 122. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 124. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 126. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
  • TABLE 128. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 129. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 131. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 133. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 135. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 159. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
  • TABLE 161. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 162. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 164. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 166. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 168. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 170. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 171. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
  • TABLE 172. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 173. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 175. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 177. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 179. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 192. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 193. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 194. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
  • TABLE 195. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 196. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 198. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 200. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 202. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 203. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 204. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 205. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
  • TABLE 206. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 207. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 209. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 211. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 213. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 214. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 223. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 224. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 225. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 226. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 227. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
  • TABLE 228. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 229. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 231. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 233. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 234. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 235. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 237. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 238. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
  • TABLE 239. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 240. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 242. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 243. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 244. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 245. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 246. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 247. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 248. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 249. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
  • TABLE 250. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 251. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 253. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 254. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 255. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 256. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 257. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 258. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 259. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 260. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 261. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
  • TABLE 262. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 263. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 265. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 266. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 267. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 268. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 270. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 271. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 272. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
  • TABLE 273. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 274. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 276. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 277. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 278. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 279. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 280. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)